Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ernest Bognar

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Gynecologic Oncology|October 27, 2021
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancerAdam Walter, Rodney P Rocconi, Bradley J Monk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2023
Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNAPeter Anderson, Maurizio Ghisoli, Brian D Crompton, et al.
Gynecologic Oncology|March 15, 2021
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancerRodney P Rocconi, Bradley J Monk, Adam Walter, et al.
Scientific Reports|July 5, 2024
3D engineered scaffold for large-scale Vigil immunotherapy productionFabienne Kerneis, Ernest Bognar, Laura Stanbery, et al.
JCO Precision Oncology|January 14, 2026
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian CancerRobert L Coleman, Rodney Rocconi, Bradley J Monk, et al.
Future Oncology (London, England)|August 5, 2024
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapyJohn Nemunaitis, Laura Stanbery, Adam Walter, et al.
Communications Medicine|September 2, 2022
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancerRodney P Rocconi, Laura Stanbery, Min Tang, et al.
Cancer Gene Therapy|March 23, 2021
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancerRodney P Rocconi, Erin E Stevens, Justin N Bottsford-Miller, et al.
Gynecologic Oncology|September 29, 2016
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancerJonathan Oh, Minal Barve, Carolyn M Matthews, et al.
The Lancet. Oncology|December 3, 2020
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trialRodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Gynecologic Oncology|October 27, 2021
Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancerAdam Walter, Rodney P Rocconi, Bradley J Monk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2023
Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNAPeter Anderson, Maurizio Ghisoli, Brian D Crompton, et al.
Gynecologic Oncology|March 15, 2021
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancerRodney P Rocconi, Bradley J Monk, Adam Walter, et al.
Scientific Reports|July 5, 2024
3D engineered scaffold for large-scale Vigil immunotherapy productionFabienne Kerneis, Ernest Bognar, Laura Stanbery, et al.
JCO Precision Oncology|January 14, 2026
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian CancerRobert L Coleman, Rodney Rocconi, Bradley J Monk, et al.
Future Oncology (London, England)|August 5, 2024
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapyJohn Nemunaitis, Laura Stanbery, Adam Walter, et al.
Communications Medicine|September 2, 2022
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancerRodney P Rocconi, Laura Stanbery, Min Tang, et al.
Cancer Gene Therapy|March 23, 2021
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancerRodney P Rocconi, Erin E Stevens, Justin N Bottsford-Miller, et al.
Gynecologic Oncology|September 29, 2016
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancerJonathan Oh, Minal Barve, Carolyn M Matthews, et al.
The Lancet. Oncology|December 3, 2020
Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trialRodney P Rocconi, Elizabeth A Grosen, Sharad A Ghamande, et al.
Pageof 2